Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
|Articles|May 27, 2021
Rheumatology Network's Spotlight: Clinical Updates in Psoriatic Arthritis May 2021
Author(s)Lana Pine
Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.
Advertisement
For more information about Psoriatic Arthritis, check out Rheumatology Network's
Advertisement
Related to this article
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for PsA.
In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.
Ruderman discusses how Northwestern's joint dermatology-rheumatology clinic shapes diagnosis and treatment of psoriatic disease.
Sonelokimab hit its primary ACR50 endpoint and all key secondary endpoints in biologic-naive patients with psoriatic arthritis in the phase 3 IZAR-1 trial.
Mease revisits the biggest PsA readouts from EULAR 2026: guselkumab, izokibep, GLP-1 combo therapy and more.
Advertisement
Advertisement